Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

Rhea-AI Summary

Monopar Therapeutics (Nasdaq: MNPR) announced that CEO Chandler D. Robinson will present a corporate update at the H.C. Wainwright 22nd Annual Global Investment Conference, focusing on healthcare and biotech. The virtual conference is scheduled for September 16, 2020, at 1:30 PM EDT. Monopar is a clinical-stage biopharmaceutical company that develops therapeutics aimed at improving the life quality of cancer patients, with a pipeline including Validive, camsirubicin, and MNPR-101.

WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 22^nd Annual Global Investment Conference, Healthcare & Biotech Track. The conference will be held virtually.

Presentation Details:

Date: Wednesday, September 16, 2020

Time: 1:30 PM EDT

Location: Virtual

https://hcwevents.com/

For more information, please contact investor relations at kimtsu@monopartx.com.

About Monopar Therapeutics Inc. 
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive^® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com. 

About H.C. Wainwright 22^nd Annual Global Investment Conference

The H.C. Wainwright 22^nd Annual Global Investment Conference featuring a Healthcare & Biotech track, will be a virtual event which includes keynote speakers, presenting companies, investor one-on-one meetings, networking opportunities and an evening of virtual entertainment. The event will occur from September 14-16, 2020. For more information on the event, visit https://hcwevents.com/.

FAQ

When will Monopar Therapeutics present at the H.C. Wainwright 22nd Annual Global Investment Conference?

Monopar Therapeutics will present on September 16, 2020, at 1:30 PM EDT.

What is the focus of Monopar Therapeutics?

Monopar Therapeutics focuses on developing therapeutics to extend life and improve quality of life for cancer patients.

Where can I find more information about the H.C. Wainwright Conference?

More information about the conference can be found at https://hcwevents.com.

What are Monopar Therapeutics' key products?

Monopar's pipeline includes Validive for oral mucositis, camsirubicin for sarcoma, and MNPR-101 for advanced cancers and severe COVID-19.